

Innovations in Cost-Disruptive Tools for Diagnosis and Screening



Before applying, applicants should familiarize themselves with the supporting documents for this Grand Challenge, including the terms and conditions of the Gates Foundation, the [Rules and Guidelines](#), [Application Instructions](#), and [Frequently Asked Questions](#).

If you are planning to apply to this RFP we will be hosting a dedicated webinar on March 30 from 8:30-9:30 AM Pacific

We use strictly necessary cookies to make our site work. We and our partners also use (with your consent) additional cookies and similar technologies to collect information when you interact with our site to improve your experience.

By clicking "Accept All," you consent to the placement of these additional cookies and similar technologies. You can change and manage your cookie settings at any time by clicking "Manage Cookies". By using the site you acknowledge the privacy practices described in our [Privacy & Cookies Notice](#) and agree to our site [Terms of Use](#).

Manage Cookies

Accept All

Diagnostics and screening underpin clinical care, surveillance, and disease control, yet many tools remain too costly, infrastructure-dependent, or operationally complex for use. The World Health Organization's (WHO) ASSURED principles, as well as the experience with malaria rapid diagnostic tests (RDTs) and community antigen testing during COVID-19, demonstrate how decentralization, low complexity, and affordability can expand reach and strengthen surveillance.^{[2],[3]} Where mature, widely deployed diagnostic classes already meet programmatic needs, pathway-changing innovation is more likely to yield impact than incremental improvements to established formats.

Beyond lowering consumable costs, the economic model must support high-volume screening through very low per-test costs and rapid throughput. Durable device- or platform-based solutions that use minimal or no consumables and amortize capital costs across large volumes, enabling near-zero incremental cost per test, can be transformational. Such approaches may draw on cross-sector technologies including imaging, acoustics, breath or environmental analyzers, contactless physiological monitors, or modular hardware with interchangeable sensing or analyte capabilities and minimal consumable inputs. In some contexts, appropriate use of artificial intelligence (AI) may enhance performance, enable task-shifting, automate quality control, and reduce operator variability, supporting high-throughput deployment in real-world LMIC workflows.

The Challenge

This Grand Challenge seeks **cost-disruptive tools for diagnosis and screening**, defined as devices that amortize capital to near-zero incremental cost and consumable \$1-class tests that materially reset the cost curve in LMICs while meeting real-world deployment constraints (see [Table 1](#)). For screening applications, cost targets should be interpreted per person screened; for diagnostic or monitoring applications, per test performed. Accordingly, this initiative aims to translate these cost-disruptive concepts into scalable solutions across high-priority disease areas.

We are particularly interested in transformative, high-risk, high-reward innovations that fundamentally rethink how diagnosis or screening is performed, including novel sensing modalities, software-defined diagnostics, and AI-enabled or software-only approaches that materially change performance, cost structure, or deployment models.

Table 2 outlines tonic areas and use cases that are in scope for this RFP. However, applicants are not required to

We use strictly necessary cookies to make our site work. We and our partners also use (with your consent) additional cookies and similar technologies to collect information when you interact with our site to improve your experience.

By clicking "Accept All," you consent to the placement of these additional cookies and similar technologies. You can change and manage your cookie settings at any time by clicking "Manage Cookies". By using the site you acknowledge the privacy practices described in our [Privacy & Cookies Notice](#) and agree to our site [Terms of Use](#).

- Clearly articulate the relevant LMIC disease focus area and intended use case from [Table 2](#), especially transformative approaches with a technically credible adaptation pathway where disease-specific validation does not yet exist.
- Describe operational feasibility for LMIC settings (see [Table 1](#)), including explicit attention to high-throughput screening workflows, where applicable.
- Include a feasible workplan and milestones appropriate to the maturity of the technology.
- Provide clear evidence to justify the requested funding level.
- Present a credible pathway to population-scale economics (approximately US\$1 or near-zero incremental cost), including key assumptions. For platform-based solutions, describe how multiple use cases can improve economics and sustainability.
- Commit to independent evaluation participation and appropriate ethical, regulatory, and Foundation open access policy.

Table 1: Cross-Cutting Design Criteria

Criterion	Expectation
Rapid results	Provides actionable results during a single patient encounter.
Ease of use	Operable by minimally trained users in decentralized settings.
LMIC robustness	Functions reliably in low-resource environments (heat, dust, intermittent power, limited infrastructure).
Cold-chain independence	Minimizes or eliminates cold-chain requirements through thermostable reagents and temperature-stable device design.
Consumables minimization	Reduces reliance on disposable consumables and favors durable, reusable hardware architectures with negligible incremental cost per screening.
Cost	Demonstrates a credible pathway to approximately US\$1 per test or near-zero incremental cost per person screened for devices.

We use strictly necessary cookies to make our site work. We and our partners also use (with your consent) additional cookies and similar technologies to collect information when you interact with our site to improve your experience.

By clicking "Accept All," you consent to the placement of these additional cookies and similar technologies. You can change and manage your cookie settings at any time by clicking "Manage Cookies". By using the site you acknowledge the privacy practices described in our [Privacy & Cookies Notice](#) and agree to our site [Terms of Use](#).

For this challenge, we are not seeking proposals that:

- Are implementation, procurement, delivery, or roll-out projects without substantive R&D or primarily consisting of large clinical trials or definitive field studies (limited, development-oriented evaluation may be appropriate).
- Are discovery-only biomarker projects without a clear pathway to a deployable prototype within three to five years, or that propose only incremental modifications of well-established approaches without a plausible step-change in cost, scalability, or screening value.
- Request funding levels that are not supported by commensurate technical readiness, feasibility evidence, and a credible pathway to validation.
- Lack a plausible pathway to meet cost and operational constraints, including reliance on expensive consumables or complex infrastructure without a credible mitigation plan.
- Are unwilling to share prototypes, reagents, and/or data as needed for third-party assessment under appropriate governance arrangements.

Award Structure

To accommodate different stages of innovation, this Challenge has multiple award sizes commensurate with technology maturity. For example:

- **Option A:** Smaller proof-of-concept awards (up to five awards of approximately US\$300,000, for each selected project, with a grant term of up to 24 months) to support early feasibility and prototyping, inclusive of technically risky, out-of-the-box concepts.
- **Option B:** Mid-level awards (up to three awards of approximately US\$500,000, for each selected project, with a grant term of up to 24 months) to support product refinement and early validation.
- **Option C:** Larger awards (up to two awards of approximately US\$1,000,000, for each selected project, with a grant term of up to 36 months) to support mature platforms or advanced adaptation toward verification and field readiness, with commensurate evidence of technical readiness, feasibility, and a clear pathway to validation.

We use strictly necessary cookies to make our site work. We and our partners also use (with your consent) additional cookies and similar technologies to collect information when you interact with our site to improve your experience.

By clicking "Accept All," you consent to the placement of these additional cookies and similar technologies. You can change and manage your cookie settings at any time by clicking "Manage Cookies". By using the site you acknowledge the privacy practices described in our [Privacy & Cookies Notice](#) and agree to our site [Terms of Use](#).

Table 2: In-Scope Topic Areas, and Opportunities

Topic area	Tuberculosis (TB)
Background	Tuberculosis requires highly scalable and extremely low-cost tools (including assays and durable device-based technologies) for both community-level, symptom-agnostic screening and accessible near-patient diagnosis.
Opportunity	A. Community and primary-care symptom-agnostic screening tools (non-sputum approaches prioritized).
	B. Diagnostic tools or devices aligned with WHO TB diagnostic TPPs, including true point-of-care tests that enable rapid confirmation outside centralized laboratories.
	Additional information: TB
Topic area	Human Immunodeficiency Virus (HIV)
Background	Sustained epidemic control hinges on decentralized viral-load (VL) monitoring, timely early infant diagnosis (EID), and reliable identification of advanced HIV disease (AHD).
Opportunity	A. Near-Point-of-care or decentralized quantitative HIV viral-load testing.
	B. Point-of-care tool for EID for infants <18 months to enable same-visit diagnosis and treatment initiation.
	C. Near-Point-of-care CD4 or AHD triage tests to identify people needing the AHD package of care.

We use strictly necessary cookies to make our site work. We and our partners also use (with your consent) additional cookies and similar technologies to collect information when you interact with our site to improve your experience.

By clicking "Accept All," you consent to the placement of these additional cookies and similar technologies. You can change and manage your cookie settings at any time by clicking "Manage Cookies". By using the site you acknowledge the privacy practices described in our [Privacy & Cookies Notice](#) and agree to our site [Terms of Use](#).

	B. Ultra-low-cost non-HRP2 pan-Plasmodium RDTs (LDH or equivalent) with high sensitivity/specificity and sustainable sub-\$1 manufacturing pathways. RDTs based solely upon HRP-2/3 as a biomarker are out of scope.
	C. AI-enabled or digitally augmented RDT platforms to improve read accuracy, performance, offer semi-quantitative interpretation, or increase workflow efficiency without increasing cost.
	Additional information: Malaria
Topic area	Sexually Transmitted Infections (STI)
Background	Syndromic management leaves many STIs undetected and drives overtreatment. HPV screening and triage that enable same-visit screen-and-treat pathways are additional high-impact prevention priorities.
Opportunity	A. Point-of-care diagnostics for gonorrhea (NG), chlamydia (CT), and trichomonas (TV) in symptomatic adults.
	B. Point-of-care diagnostics for active adult and congenital syphilis with $\geq 90\%$ sensitivity $\geq 95\%$ specificity in populations, including neonates to inform treatment.
	C. Point-of-care tools for high-risk HPV primary screening, with $\geq 95\%$ sensitivity for CIN2+ and $\geq 99\%$ specificity for \leq CIN 1, enabling same-visit screen-and-treat for cervical precancer.
	D. Platforms supporting modular expansion to additional STI analytes (e.g., BV) and programmatic throughput.

We use strictly necessary cookies to make our site work. We and our partners also use (with your consent) additional cookies and similar technologies to collect information when you interact with our site to improve your experience.

By clicking "Accept All," you consent to the placement of these additional cookies and similar technologies. You can change and manage your cookie settings at any time by clicking "Manage Cookies". By using the site you acknowledge the privacy practices described in our [Privacy & Cookies Notice](#) and agree to our site [Terms of Use](#).

	B. Simplified, non-fasting or minimally invasive new biomarker-based approaches for gestational hyperglycemia detection/monitoring.
	C. Rapid Point-of-care tools for neonatal sepsis triage to guide treatment escalation decisions and/or identify neonates who can safely avoid or step down from intensive care.
	D. Tools for earlier identification of infectious disease outbreak clusters in neonatal intensive care units (NICU).
	E. Triage tool for heavy menstrual bleeding (HMB) to rule out structural etiologies and identify ovarian abnormalities (e.g. biomarker panel or AI-enabled tool).
	Additional information: Maternal and Newborn Health
Topic area	Anemia and Women's Health
Background	Anemia remains highly prevalent in key risk groups (children, adolescents, women of reproductive age, pregnant women, and lactating mothers), and routine hemoglobin testing is often limited by invasive sampling and infrastructure constraints, leading to missed or delayed identification and treatment.
Opportunity	A. Non-invasive anemia screening tool for community-level mass screening or primary-care-level triage.
	B. Point-of-care, minimally invasive diagnostic to distinguish iron deficiency anemia from other causes, including for severity testing, repeat testing in ANC and postpartum, for evaluation of heavy menstrual bleeding, and for micronutrient assessment.

We use strictly necessary cookies to make our site work. We and our partners also use (with your consent) additional cookies and similar technologies to collect information when you interact with our site to improve your experience.

By clicking "Accept All," you consent to the placement of these additional cookies and similar technologies. You can change and manage your cookie settings at any time by clicking "Manage Cookies". By using the site you acknowledge the privacy practices described in our [Privacy & Cookies Notice](#) and agree to our site [Terms of Use](#).

	B. High-throughput laboratory or multiplex workflows that support repeated biomarker measurement through integration with existing infectious disease surveillance systems.
	C. Rapid tests that give quantitative or semi-quantitative on-site readouts of micronutrient content (particularly zinc or folic acid) in fortified food matrices to inform quality assurance.
	Additional information: Nutrition Surveillance and Fortified-Food Monitoring
Topic area	Enteric Diseases
Background	Enteric infections (including typhoid, cholera, and pediatric diarrhea pathogens) remain a major driver of morbidity and mortality in LMICs and can trigger outbreaks requiring rapid public-health action. Accurate, near-patient diagnostics are essential not only for clinical management and antimicrobial stewardship, but also for surveillance and vaccine policy decisions, as vaccines are available or in development for several high-burden enteric pathogens.
Opportunity	A. Point-of-care test to detect acute <i>Salmonella enterica</i> serovar Typhi infection with $\geq 90\%$ sensitivity and $\geq 90\%$ specificity.
	B. Acute <i>Shigella</i> diagnostic that detects <i>Shigella spp.</i> with high accuracy in the same patient encounter.
	C. Acute bacterial diarrhea diagnostic with high accuracy to distinguish bacterial from non-bacterial diarrhea in the same patient encounter.
	D. Near-patient cholera confirmatory test to detect toxigenic <i>Vibrio cholerae</i> (O1/O139 and/or cholera-toxin markers) with $\geq 95\%$ sensitivity and $\geq 97\%$ specificity, enabling faster

We use strictly necessary cookies to make our site work. We and our partners also use (with your consent) additional cookies and similar technologies to collect information when you interact with our site to improve your experience.

By clicking "Accept All," you consent to the placement of these additional cookies and similar technologies. You can change and manage your cookie settings at any time by clicking "Manage Cookies". By using the site you acknowledge the privacy practices described in our [Privacy & Cookies Notice](#) and agree to our site [Terms of Use](#).

Opportunity	A. Diagnostics that detect active infection vs. prior exposure to support stopping MDA and post-validation surveillance decisions.
	B. Point-of-care tests detecting circulating parasite antigens or other biomarkers of ongoing infection (e.g., in lymphatic filariasis or onchocerciasis) to improve specificity for transmission.
	C. Non-blood-based diagnostics that reduce operational barriers such as night blood collection in lymphatic filariasis and improve feasibility in elimination settings.
	D. Diagnostic tool for identifying prepatent or early patent Guinea worm infection in dogs to facilitate surveillance and targeted containment.
	E. High-throughput, integrated serology tests for mapping post-MDA surveillance across multiple NTDs (e.g., onchocerciasis, lymphatic filariasis, schistosomiasis, soil-transmitted helminths), with high sensitivity and specificity at low prevalence.
	Additional information: NTD
Topic area	Emerging Pathogens and Syndromic Testing
Background	Rapid detection, scalable surveillance, and surge-ready manufacturing are critical to shortening the time from pathogen emergence to population-level response. Diagnostics must be rapidly adaptable to new analytes, support decentralized triage and screening, and integrate with surveillance and early-warning systems in low-resource settings.
Opportunity	A. Rapidly reconfigurable, modular, open-architecture platforms capable of quick adaptation for new or emerging pathogens and capable of automated reporting to public health

We use strictly necessary cookies to make our site work. We and our partners also use (with your consent) additional cookies and similar technologies to collect information when you interact with our site to improve your experience.

By clicking "Accept All," you consent to the placement of these additional cookies and similar technologies. You can change and manage your cookie settings at any time by clicking "Manage Cookies". By using the site you acknowledge the privacy practices described in our [Privacy & Cookies Notice](#) and agree to our site [Terms of Use](#).

Topic area	Manufacturing Innovations
Background	Novel manufacturing techniques that increase scale, automate processes, and/or improve usable product yield can be critical in driving down the cost of diagnostic consumables enabling existing technologies to meet the \$1-class diagnostic target.
Opportunity	A. Manufacturing innovations that reduce the cost of diagnostic consumables (e.g. reagents, lateral flow assays, microfluidic cartridges).
	B. Novel approaches to reduce device component costs by leveraging the latest advances in sensors and chip technologies - enabling higher integration and functionality with fewer components and simpler system architectures.

[1] Fleming KA et al. [The Lancet Commission on diagnostics: transforming access to diagnostics](#). The Lancet, Volume 398, Issue 10315. 2021.

[2] Land KJ, et al. [REASSURED diagnostics to inform disease control strategies, strengthen health systems and improve patient outcomes](#). Nat Microbiol. 2019; 4(1):46-54.

[3] Kerr G, et al. [Lessons for improved COVID-19 surveillance from the scale-up of malaria testing strategies](#). Malar J. 2022; 21:223.

Initiative: Grand Challenges

Challenge Topic: Diagnosis and Screening

Date Open: Mar 17, 2026, 9:00 am PDT

Deadline: Apr 28, 2026, 11:30 am PDT

Supporting Materials:

We use strictly necessary cookies to make our site work. We and our partners also use (with your consent) additional cookies and similar technologies to collect information when you interact with our site to improve your experience.

By clicking "Accept All," you consent to the placement of these additional cookies and similar technologies. You can change and manage your cookie settings at any time by clicking "Manage Cookies". By using the site you acknowledge the privacy practices described in our [Privacy & Cookies Notice](#) and agree to our site [Terms of Use](#).

We use strictly necessary cookies to make our site work. We and our partners also use (with your consent) additional cookies and similar technologies to collect information when you interact with our site to improve your experience.

By clicking "Accept All," you consent to the placement of these additional cookies and similar technologies. You can change and manage your cookie settings at any time by clicking "Manage Cookies". By using the site you acknowledge the privacy practices described in our [Privacy & Cookies Notice](#) and agree to our site [Terms of Use](#).